ARTICLE | Emerging Company Profile
Carbon: a non-AAV gene therapy for cystic fibrosis with repeat dosing potential
Agent Capital leads $38M series A for company emerging from incubator established by Longwood, CF Foundation
June 21, 2022 11:24 AM UTC
Incubated via a collaboration between the Cystic Fibrosis Foundation and Longwood Fund, newly launched Carbon believes its non-AAV parvoviral vectors could address disorders previously untreatable with gene therapies, starting with CF.
Carbon Biosciences Inc. will move lead program CGT-001 through IND-enabling work on the strength of a $38 million series A round led by Agent Capital. The gene therapy uses a “lung-tropic” parvoviral vector to deliver the whole CFTR gene to CF patients, CEO Joel Schneider told BioCentury...